1. The Italian INTERCEPTOR Project: From the Early Identification of Patients Eligible for Prescription of Antidementia Drugs to a Nationwide Organizational Model for Early Alzheimer's Disease Diagnosis.
- Author
-
Rossini, Paolo Maria, Cappa, Stefano F., Lattanzio, Fabrizia, Perani, Daniela, Spadin, Patrizia, Tagliavini, Fabrizio, and Vanacore, Nicola
- Subjects
- *
ALZHEIMER'S disease , *DRUGS , *DIAGNOSIS , *MILD cognitive impairment , *AUTONOMY (Psychology) , *DIAGNOSIS of dementia , *ALZHEIMER'S disease diagnosis , *RESEARCH , *PSYCHIATRIC drugs , *RESEARCH methodology , *PUBLIC health , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *DEMENTIA , *EARLY diagnosis - Abstract
Alzheimer's disease is the most common age-related neurodegenerative disorder and its burden on patients, families, and society grows significantly with lifespan. Early modifications of risk-enhancing lifestyles and treatment initiation expand personal autonomy and reduce management costs. Many clinical trials with potentially disease-modifying drugs are devoted to mild cognitive impairment (MCI) prodromal-to-Alzheimer's disease. The identification of biomarkers for early diagnosis may thus be crucial for early intervention and identification of high-risk subjects, the most appropriate target of new drugs as soon as they will be discovered. INTERCEPTOR is a strategic project by the Italian Ministry of Health and the Italian Medicines Agency (AIFA), aiming to validate the best combination (highly accurate, non-invasive, available on the whole national territory and financially sustainable) of biomarkers and organizational model for early diagnosis. 500 MCI subjects will be enrolled at baseline and followed-up for 3 years for at least 400 of them in order to define a "hub & spoke" nationwide model with recruiting (spokes) centers for MCI identification and expert (hubs) centers for risk diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF